- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
SLIDESHOW: Overview of July 2024 FDA Approvals
Author(s):
Take a deep dive into the 3 approvals for various dermatological conditions this month.
References
1. Andrus A. FDA approves biosimilar ustekinumab-ttwe for all indications of reference medicine. Dermatology Times. July 1, 2024. Accessed July 30, 2024. https://www.dermatologytimes.com/view/fda-approves-biosimilar-ustekinumab-ttwe-for-all-indications-of-reference-medicine
2. Bader K. FDA approves roflumilast cream 0.15% for atopic dermatitis in patients aged 6 years and older. Dermatology Times. July 9, 2024. Accessed July 30, 2024. https://www.dermatologytimes.com/view/fda-approves-roflumilast-cream-0-15-for-atopic-dermatitis-in-patients-aged-6-years-and-older
3. Buchanan L. The FDA approves deuruxolitinib for severe alopecia in adults. Dermatology Times. July 26, 2024. Accessed July 30, 2024. https://www.dermatologytimes.com/view/the-fda-approves-deuruxolitinib-for-severe-alopecia-in-adults
